Ironwood Pharmaceuticals to Present at the 29th Annual Credit Suisse Healthcare Conference
Ironwood Pharmaceuticals (NASDAQ: IRWD) will engage in a virtual fireside chat during the 29th Annual Credit Suisse Healthcare Conference on November 11, 2020, at 3:30 p.m. ET. Interested listeners can access the live webcast via the Investors section of Ironwood's website, starting 15 minutes before the event. A replay will be available for 14 days post-conference. Ironwood focuses on developing treatments for gastrointestinal diseases and is known for its linaclotide product, a leader in the U.S. market for IBS-C and CIC.
- None.
- None.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in a virtual fireside chat at the 29th Annual Credit Suisse Healthcare Conference on Wednesday, November 11, 2020 at 3:30 p.m. Eastern Time.
A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Ironwood was founded in 1998 and is headquartered in Boston, Mass. For more information, please visit our website at www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.
